The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC

Cisplatin is one of the most common chemotherapeutic drugs for non-small cell lung cancer (NSCLC). However, the response rate is limited because of drug resistance. Histone deacetylase inhibitors (HDACis), which can alter DNA accessibility by regulating chromatin structure and inducing apoptosis, ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Yang, Yan, Xiang, Zhang, Guoqing, Zhao, Weihong, Jiao, Shunchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662470/
https://www.ncbi.nlm.nih.gov/pubmed/25944617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662470/
https://www.ncbi.nlm.nih.gov/pubmed/25944617

Ejemplares similares